Home › Funds › RTW INVESTMENTS, LP › SYRE

RTW INVESTMENTS, LP position in SYRE

SPYRE THERAPEUTICS INC · Health Care

RTW INVESTMENTS, LP reported holding 3,691,791 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$328.7M, representing 3.32% of its reported portfolio and ranking #8 among its reported holdings. RTW INVESTMENTS, LP has disclosed SYRE holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)3.69M sh
Reported value held$328.68M
Portfolio Weight3.32%
First reportedQ4 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How RTW INVESTMENTS, LP's SYRE position evolved

RTW INVESTMENTS, LP first disclosed a stake in SYRE in Q4 2023 at 2,232,760 shares (US$48.0M). The position peaked in Q2 2026 at 4,251,996 shares, worth US$377.5M. Across 12 filings, RTW INVESTMENTS, LP increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 3,691,791 shares valued at US$328.7M — a reduction of -560,205 shares quarter over quarter.. Notable position changes include a 46% increase in Q2 2024 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 2.23M $48.05M New
Q1 2024 2.23M $84.69M Hold
Q2 2024 3.26M $76.60M Add
Q3 2024 3.26M $95.83M Hold
Q4 2024 3.62M $84.32M Add
Q1 2025 3.62M $58.44M Hold
Q2 2025 3.62M $54.22M Hold
Q3 2025 3.62M $60.70M Hold
Q4 2025 4.17M $136.67M Add
Q1 2026 4.17M $210.44M Hold
Q2 2026 4.25M $377.49M Add
Q3 2026 3.69M $328.68M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SYRE and 13F data

SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 64 other funds we track also report a position in SYRE — the largest reported positions include Paradigm Biocapital Advisors LP (US$396.8M), PERCEPTIVE ADVISORS LLC (US$383.5M), Venrock Adviser, LLC (US$265.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SYRE

All SYRE fund holders →

FAQ

How long has RTW INVESTMENTS, LP held SYRE?

RTW INVESTMENTS, LP has disclosed SYRE holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is RTW INVESTMENTS, LP's current position in SYRE?

As of Q3 2026, RTW INVESTMENTS, LP holds 3.69M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $328.68M, representing 3.32% of its reported portfolio and ranking #8.

Has RTW INVESTMENTS, LP been buying or selling SYRE?

In the latest 13F filing (Q3 2026), RTW INVESTMENTS, LP reduced its position in SYRE. The position peaked in Q2 2026 at 4.25M shares.

Which other funds hold SYRE?

Other major institutional holders of SYRE include Paradigm Biocapital Advisors LP, PERCEPTIVE ADVISORS LLC, Venrock Adviser, LLC, among 64 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.